TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03589885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 mL auto-injector
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 mL prefilled syringe
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 2 mL auto-injector
Description: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 1 mL prefilled syringe
Description: 2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study: NCT03277144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TST-TriStaple(3lines stapler)Technology
Description: Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
Study: NCT02525796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: eplerenone, titrated up to a maximum of 50mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: amiloride, titrated up to a maximum of 10mg BID
Study: NCT03277144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: other conventional techniques
Description: Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
Study: NCT02525796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
Study: NCT02213913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03168321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Tazarotene 0.045% Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-123 Vehicle Lotion
Description: Vehicle Lotion
Study: NCT02992626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-dog interaction
Description: The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-dog interaction
Description: The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stuffed toy dog
Description: The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stuffed toy dog
Description: The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
Study: NCT02960438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration
Study: NCT03686150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation
Study: NCT01723410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing about people
Description: Subjects will be asked to write about other people in their lives once a week for 6-weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing about places, objects
Study: NCT03565939

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris suis ova
Description: Eggs from the pig whipworm
Study: NCT03686150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation
Study: NCT01072786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 1
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 2
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 3
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 4
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 5
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
Study: NCT00017394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01098994

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin E
Description: Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin E
Description: Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin E
Description: Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Dummy pills
Description: Daily placebo administration for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Dummy pills
Description: Daily placebo administration for 8 weeks
Study: NCT03565939

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution without TSO
Study: NCT01199783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Infusion (6 mg/kg/bodyweight) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
Study: NCT01098994

Intervention type: OTHER
Group type: OTHER
Intervention: Dummy pills
Description: Daily placebo administration for 8 weeks
Study: NCT02689999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrabeprazole 10 mg Enteric-Coated Tablets
Study: NCT05927181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAOM
Description: In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAOM
Description: In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
Study: NCT02148913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Carfilzomib 15 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: Carfilzomib 20 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2b: Carfilzomib 20 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3b: Carfilzomib 27 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
Study: NCT01090375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Exercise
Study: NCT03648346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: HL217 Ophathalmic Solution BID
Description: Two drops of 3 mg/mL of the treatment in one eye twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: HL217 Ophathalmic Solution QID
Description: Two drops of 3 mg/mL of the treatment in one eye 4 times a day
Study: NCT01912716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose indomethacin
Description: patients randomized to this intervention receive 200mg indomethacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose indomethacin
Description: patients randomized to this intervention receive 100mg indomethacin
Study: NCT02152202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-upright position
Description: In this group patients' bed will be set into 45 degree angle during sleep in the night time.

Intervention type: OTHER
Group type: OTHER
Intervention: Supine position
Description: Control: Supine position during nocturnal sleep for at least two postoperative nights.
Study: NCT02857829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAF+
Description: CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine-alone
Description: Caffeine (100 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour
Study: NCT00733031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6918
Description: liquid suspension, daily, oral dose
Study: NCT03648346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study: NCT03400254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
Study: NCT00733031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: intravenous, doses are on an intermittent schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous, dose administered every 21-days
Study: NCT03452618

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnosis variables
Description: The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnosis variables
Description: The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)
Study: NCT00190242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group1
Description: Havrix at 1440IU was administrated à weeks S0, S4 and S24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group2
Description: Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
Study: NCT03016338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 or 300 mg daily PO, for 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: 500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
Study: NCT02036450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (Medtronic Reveal LINQ(TM))
Description: The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
Study: NCT01973452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT02504723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate
Description: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
Study: NCT01246960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study: NCT00716820

Intervention type: DRUG
Intervention: SUNITINIB MALATE
Description: SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition.
Study: NCT03738917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan 15 milligrams
Description: This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
Study: NCT01973452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03738917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide 20Micrograms Inhaler
Description: This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey 30 g (full tablespoon)
Description: This study product will be provided free to the participants by the sponsor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual clinical practice
Description: Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
Study: NCT04636632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant
Description: fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
Study: NCT04636632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
Study: NCT04127318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedaling Group
Description: Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
Study: NCT01746524

Intervention type: DEVICE
Intervention: ATTUNE Primary Total Knee Arthroplasty
Description: Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).

Intervention type: DEVICE
Intervention: ATTUNE Primary Total Knee Arthroplasty
Description: Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).

Intervention type: DEVICE
Intervention: ATTUNE Primary Total Knee Arthroplasty
Description: Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).

Intervention type: DEVICE
Intervention: ATTUNE Primary Total Knee Arthroplasty
Description: Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).